| Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan. The EXEL YTD return is shown above.
The YTD Return on the EXEL YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether EXEL YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EXEL YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.